Biodexa Pharmaceuticals Plc (BDRX) - News Archive

Showing 4 of 4 results.

Biodexa Pharmaceuticals Announces Positive Phase I Results for Diffuse Midline Glioma Treatment, Offering New Hope for Patients

Biodexa Pharmaceuticals PLC Presents Positive Top Line Phase I Clinical Trial Results for Diffuse Midline Glioma and Provides R&D UpdateIn a recent press release, Biodexa Pharmaceuticals PLC (Biodexa) announced the posi...

Feb 23, 2024 • Major Pharmaceutical Preparations Industry Clinical Study

Biodexa Pharmaceuticals PLC Raises $6.0 Million in Public Offering, Ushering in a New Era of Innovative Therapeutics

Biodexa Pharmaceuticals PLC Successfully Closes $6.0 Million Public Offering, Demonstrating Investor Confidence in Innovative Therapeutics Biodexa Pharmaceuticals PLC(Biodexa or the Company)In a stellar display of marke...

Dec 21, 2023 • Major Pharmaceutical Preparations Industry Equity Market Information oncology

Biodexa Pharmaceuticals PLC Leads the Charge in Innovative Glioblastoma Treatment Study while Surpassing Competitors in Revenue Growth

In a groundbreaking development within the pharmaceutical industry, Biodexa Pharmaceuticals PLC (Biodexa) has successfully completed the recruitment for Cohort A in its study of MTX110, a potential treatment for recurre...

Oct 3, 2023 Partnership oncology

Biodexa to Present Recruitment and Treatment Update in Phase 1 Study of MTX-110 (MAGIC-G1 Study) in Patients with Recurrent Glioblastoma at 2023 Annual European Association of Neuro-Oncology Meeting (EANO)

Biodexa Pharmaceuticals PLC (Biodexa or the Company) will be sharing exciting updates regarding their ongoing clinical trial, the Phase 1 study of MTX-110 (MAGIC-G1 Study), during the upcoming 2023 Annual European Assoc...

Sep 21, 2023 Partnership oncology